mAb Development

Aug 15, 2016
By BioPharm International Editors
Jacobs Engineering will provide engineering and construction services to expand the Novartis site in Huningue, France.
Aug 01, 2016
BioPharm International
The study demonstrates a systematic approach to stabilize PBS-formulated mAbs against freeze-thaw degradation.
Jul 28, 2016
By BioPharm International Editors
NIST’s monoclonal antibody reference material can be used as a standard for biopharmaceutical analytical quality control.
Jul 26, 2016
The mAb, in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, was granted a Breakthrough Therapy Designation from FDA for the treatment of multiple myeloma.
Jul 25, 2016
By BioPharm International Editors
The companies filed a BLA for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis.
Jul 05, 2016
By BioPharm International Editors
The acquisition will give Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program.
Jun 10, 2016
In Phase III clinical trials, ixekizumab showed to be superior to etanercept and placebo in treating moderate-to-severe plaque psoriasis.
Jun 06, 2016
New research presented at the American Society of Clinical Oncology meeting demonstrates that atezolizumab could be a promising first-line therapy for the treatment of bladder cancer in cisplatin-ineligible patients.
Apr 25, 2016
By BioPharm International Editors
The agency publishes draft guidance on assay development and validation for immunogenicity testing.
Apr 18, 2016
Linker technology and drug combinations play an important role in the efficacy of ADCs.
native1_300x100
lorem ipsum